Catalent Inc (NYSE:CTLT)
| 67.49 Delayed Data As of 3:59pm ET |  +3.22 / +5.01%Today’s Change | 40.69 Today|||52-Week Range 115.34 | +49.94% Year-to-Date |
Latest CTLT News | Press Releases
| 2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch Mar 25 / MotleyFool.com - Paid Partner Content | Zoetis (ZTS) Down 6.5% Since Last Earnings Report: Can It Rebound? Mar 16 / Zacks.com - Paid Partner Content |
| Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses Mar 24 / Zacks.com - Paid Partner Content | Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines Mar 16 / Zacks.com - Paid Partner Content |
| Catalent (CTLT) Inks Deal for New & Effective Drug Delivery Mar 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 64.27 |
| Today’s open | 65.03 |
| Day’s range | 64.94 - 68.80 |
| Volume | 2,023,128 |
| Average volume (3 months) | 2,700,469 |
| Market cap | $11.6B |
Data as of 3:59pm ET, 03/27/2023
Growth & Valuation
| Earnings growth (last year) | -9.24% |
| Earnings growth (this year) | -18.19% |
| Earnings growth (next 5 years) | +7.72% |
| Revenue growth (last year) | +20.76% |
| P/E ratio | 29.6 |
| Price/Sales | 3.96 |
| Price/Book | 2.40 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SRPTSarepta Therapeutics... | +0.81 | +0.62% |
| ---- | ||
| VTRSViatris Inc | +0.14 | +1.50% |
| ---- |
Data as of 3:59pm ET, 03/27/2023
Financials
| Next reporting date | May 2, 2023 |
| EPS forecast (this quarter) | $0.65 |
| Annual revenue (last year) | $4.8B |
| Annual profit (last year) | $503.0M |
| Net profit margin | 10.42% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Somerset, New Jersey |
Forecasts
